| Collegium Announces $25 Million Accelerated Share Repurchase Program |
STOUGHTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it has entered into an Accelerated Share Repurchase ("ASR") agreement with Jefferies LLC to repurchase $25 million of the Company's common stock. Collegium will execute the ASR as part of the $150 million share repurchase program authorized by its Board of Directors in January 2024. Upon completion of this ASR, Collegium will have $65 million remaining under the program. |
globenewswire.com |
2025-05-12 12:05:00 |
Czytaj oryginał (ang.) |
| Collegium Pharmaceutical, Inc. (COLL) Q1 2025 Earnings Call Transcript |
Call Start: 16:30 January 1, 0000 5:05 PM ET Collegium Pharmaceutical, Inc. (NASDAQ:COLL ) Q1 2025 Earnings Call May 8, 2025 16:30 ET Company Participants Ian Karp - Head, Investor Relations Vikram Karnani - President and Chief Executive Officer Colleen Tupper - Chief Financial Officer Scott Dreyer - Chief Commercial Officer Conference Call Participants Les Sulewski - Truist Securities Serge Belanger - Needham & Co David Amsellem - Piper Sandler Operator Greetings and welcome to the Collegium Pharmaceutical First Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note that this conference call is being recorded. |
seekingalpha.com |
2025-05-09 06:04:21 |
Czytaj oryginał (ang.) |
| Compared to Estimates, Collegium Pharmaceutical (COLL) Q1 Earnings: A Look at Key Metrics |
The headline numbers for Collegium Pharmaceutical (COLL) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2025-05-08 22:31:10 |
Czytaj oryginał (ang.) |
| Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Surpass Estimates |
Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.49 per share, beating the Zacks Consensus Estimate of $1.43 per share. This compares to earnings of $1.45 per share a year ago. |
zacks.com |
2025-05-08 22:20:47 |
Czytaj oryginał (ang.) |
| Collegium Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress |
– Generated Q1'25 Quarterly Net Revenue of $177.8 Million, Up 23% Year-over-Year – – Grew Jornay PM ® Prescriptions by 24% Year-over-Year and Reported Quarterly Net Revenue of $28.5 Million; Jornay PM Prescribers Reached an All-Time-High – – Completed Jornay PM Field Force Expansion – – Generated Net Revenue of $149.2 Million from the Pain Portfolio, Up 3% Year-over-Year with All Three Core Products Recording Revenue Growth in the Quarter – – Ended Q1'25 with Cash, Cash Equivalents and Marketable Securities of $197.8 Million – – Board of Directors Authorized $25.0 Million Accelerated Share Repurchase Program – – Reaffirmed Full-Year 2025 Guidance – – Conference Call Scheduled for Today at 4:30 p.m. ET – STOUGHTON, Mass. |
globenewswire.com |
2025-05-08 20:01:00 |
Czytaj oryginał (ang.) |
| Collegium Pharmaceutical (COLL) Expected to Beat Earnings Estimates: Should You Buy? |
Collegium Pharmaceutical (COLL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-05-01 15:08:06 |
Czytaj oryginał (ang.) |
| Collegium to Report First Quarter 2025 Financial Results on May 8, 2025 |
STOUGHTON, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report first quarter 2025 financial results after the market closes on Thursday, May 8, 2025. |
globenewswire.com |
2025-04-24 12:00:00 |
Czytaj oryginał (ang.) |
| Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2025-04-23 14:45:49 |
Czytaj oryginał (ang.) |
| Collegium to Participate in 24th Annual Needham Virtual Healthcare Conference |
STOUGHTON, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that management will participate in a fireside chat at the 24th Annual Needham Healthcare Conference being held virtually from April 7-10, 2025. |
globenewswire.com |
2025-04-01 12:00:00 |
Czytaj oryginał (ang.) |
| Collegium to Present Real-World Data at PainConnect 2025, the American Academy of Pain Medicine's Annual Meeting |
STOUGHTON, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will present four posters highlighting real-world patient data from its differentiated pain portfolio at PainConnect 2025, the American Academy of Pain Medicine (AAPM)'s Annual Meeting, being held in Austin, TX, from April 3-6, 2025. |
globenewswire.com |
2025-03-27 10:00:00 |
Czytaj oryginał (ang.) |
| Collegium Announces Updates to its Board of Directors and Executive Leadership Team |
– Gino Santini Appointed as Chairman of the Board, Michael Heffernan, Founder and Chairman and Gwen A. Melincoff, Board Member to Retire from Board – |
globenewswire.com |
2025-03-17 09:00:00 |
Czytaj oryginał (ang.) |
| Collegium Announces Poster Presentations at the 2025 National Association of Pediatric Nurse Practitioners National Conference on Pediatric Health Care |
STOUGHTON, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will have two poster presentations highlighting real-world data from its differentiated neuropsychiatry product, Jornay PM, (methylphenidate HCl), a central nervous system (CNS) stimulant for the treatment of attention deficit hyperactivity disorder (ADHD) at the National Association of Pediatric Nurse Practitioners (NAPNAP) 46th National Conference on Pediatric Health Care, being held in Chicago, IL, from March 10-13, 2025. |
globenewswire.com |
2025-03-10 20:57:00 |
Czytaj oryginał (ang.) |
| Collegium Pharmaceutical's Shareholders Might Be In For A Pain-Free 2025 |
Collegium Pharmaceutical Inc. is a specialty pharma company with strong cash flow, high EBITDA margins, and a focus on non-abusive painkillers and ADHD drugs. The new CEO has a proven track record, previously growing Horizon's revenue from $300 million to $4 billion and selling it to Amgen for $28 billion. The stock is undervalued at 4.5x EBITDA 2024, with potential for re-rating as Jornay PM ramps up and reduces the impact of Nucynta's exclusivity loss. |
seekingalpha.com |
2025-03-09 06:07:46 |
Czytaj oryginał (ang.) |
| Collegium to Participate in Upcoming Investor Conferences |
STOUGHTON, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that management will participate in investor meetings at the following investor conferences: Leerink Partners 2025 Global Healthcare Conference Tuesday, March 11, 2025 Jefferies Biotech on the Beach Summit Wednesday, March 12, 2025 Barclays 27 th Annual Global Healthcare Conference Thursday, March 13, 2025 About Collegium Pharmaceutical, Inc. Collegium is building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. |
globenewswire.com |
2025-03-04 10:00:00 |
Czytaj oryginał (ang.) |
| Collegium Pharmaceutical, Inc. (COLL) Q4 2024 Earnings Call Transcript |
Collegium Pharmaceutical, Inc. (NASDAQ:COLL ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Danielle Jesse - Director, Investor Relations Vikram Karnani - President & Chief Executive Officer Scott Dreyer - Chief Commercial Officer Colleen Tupper - Chief Financial Officer Conference Call Participants Les Sulewski - Truist Securities David Amsellem - Piper Sandler Operator Greetings and welcome to the Collegium Pharmaceuticals Fourth Quarter and Full Year 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2025-02-27 23:03:03 |
Czytaj oryginał (ang.) |
| Collegium Pharmaceutical (COLL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates |
The headline numbers for Collegium Pharmaceutical (COLL) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2025-02-27 22:00:31 |
Czytaj oryginał (ang.) |
| Collegium Pharmaceutical (COLL) Q4 Earnings and Revenues Beat Estimates |
Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.77 per share, beating the Zacks Consensus Estimate of $1.54 per share. This compares to earnings of $1.58 per share a year ago. |
zacks.com |
2025-02-27 20:45:26 |
Czytaj oryginał (ang.) |
| Collegium Reports Record Fourth Quarter and Full-Year 2024 Financial Results |
– Generated Record Quarterly and Full-Year Net Revenue of $181.9 Million and $631.4 Million – – Reported Quarterly Jornay PM ® Net Revenue of $29.3 Million and Pro Forma Full-Year Net Revenue of $100.7 Million – – Achieved Quarterly and Full-Year GAAP Net Income of $12.5 Million and $69.2 Million – – Delivered Record Quarterly and Full-Year Adjusted EBITDA of $107.7 Million and $401.2 Million – – Ended 2024 with Cash, Cash Equivalents and Marketable Securities of $162.8 Million; Repurchased $60.0 Million in Shares in 2024 – – Reaffirmed Full-Year 2025 Guidance – – Conference Call Scheduled for Today at 4:30 p.m. ET – STOUGHTON, Mass. |
globenewswire.com |
2025-02-27 18:01:00 |
Czytaj oryginał (ang.) |
| Seeking Clues to Collegium Pharmaceutical (COLL) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics |
Evaluate the expected performance of Collegium Pharmaceutical (COLL) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight. |
zacks.com |
2025-02-26 12:15:29 |
Czytaj oryginał (ang.) |
| Collegium to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025 |
STOUGHTON, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report fourth quarter and full-year 2024 financial results after the market closes on Thursday, February 27, 2025. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET. |
globenewswire.com |
2025-02-13 10:00:00 |
Czytaj oryginał (ang.) |
| Collegium Provides 2025 Financial Guidance and Business Update |
– Product Revenues, Net Expected in the Range of $735 Million to $750 Million – – Jornay PM ® Net Revenue Expected to be in Excess of $135 Million – – Adjusted EBITDA* Expected in the Range of $435 Million to $450 Million – – Adjusted Operating Expenses* Expected in the Range of $220 Million to $230 Million – STOUGHTON, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced its 2025 full-year financial guidance and provided a business update. |
globenewswire.com |
2025-01-08 10:00:00 |
Czytaj oryginał (ang.) |
| Collegium Pharmaceutical: Strong Growth With Pain Management And ADHD Expansion |
Collegium Pharmaceutical's pain management portfolio, including Xtampza ER and Belbuca, drives 92.8% of revenues, demonstrating its market leadership in abuse-deterrent therapies. The acquisition of Jornay PM expands COLL's portfolio into neurology, tapping into the rapidly growing ADHD market, which is projected to reach $30.6 billion by 2032. Collegium reported strong Q3 2024 results, with 17% YoY revenue growth and EBIT margins improving to 35.2%, showcasing operational efficiency. |
seekingalpha.com |
2024-11-26 10:00:00 |
Czytaj oryginał (ang.) |
| Knight Therapeutics Announces Health Canada Approval for JORNAY PM™ to Treat Attention-Deficit Hyperactivity Disorder (ADHD) |
MONTREAL, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that Health Canada has approved JORNAY PM™, an extended-release formulation of methylphenidate, a stimulant medication for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in children. |
globenewswire.com |
2024-11-14 18:30:00 |
Czytaj oryginał (ang.) |
| Is Collegium Pharmaceutical (COLL) a Great Value Stock Right Now? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2024-11-13 12:45:42 |
Czytaj oryginał (ang.) |
| Is the Options Market Predicting a Spike in Collegium Pharmaceutical (COLL) Stock? |
Investors need to pay close attention to Collegium Pharmaceutical (COLL) stock based on the movements in the options market lately. |
zacks.com |
2024-11-08 11:35:18 |
Czytaj oryginał (ang.) |
| Collegium Pharmaceutical, Inc. (COLL) Q3 2024 Earnings Call Transcript |
Collegium Pharmaceutical, Inc. (NASDAQ:COLL ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Danielle Jesse - Director, Investor Relations Michael Heffernan - Interim President and Chief Executive Officer, Founder and Chairman Scott Dreyer - Chief Commercial Officer Colleen Tupper - Chief Financial Officer Conference Call Participants Les Sulewski - Truist Securities David Amsellem - Piper Sandler Serge Belanger - Needham & Company Oren Livnat - H.C. Wainright Operator Greetings, and welcome to the Collegium Pharmaceutical Third Quarter 2024 Earnings Conference Call. |
seekingalpha.com |
2024-11-08 02:30:28 |
Czytaj oryginał (ang.) |
| Here's What Key Metrics Tell Us About Collegium Pharmaceutical (COLL) Q3 Earnings |
While the top- and bottom-line numbers for Collegium Pharmaceutical (COLL) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
zacks.com |
2024-11-07 21:30:44 |
Czytaj oryginał (ang.) |
| Collegium Pharmaceutical (COLL) Q3 Earnings and Revenues Lag Estimates |
Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.61 per share, missing the Zacks Consensus Estimate of $1.66 per share. This compares to earnings of $1.34 per share a year ago. |
zacks.com |
2024-11-07 20:37:37 |
Czytaj oryginał (ang.) |
| Collegium Reports Record Third Quarter 2024 Financial Results |
– Generated Record Q3'24 Net Revenue of $159.3 Million, Up 17% Year-over-Year, Driven by Record Belbuca ® Revenue of $53.2 Million and Record Xtampza ® ER Revenue of $49.5 Million – |
globenewswire.com |
2024-11-07 18:02:00 |
Czytaj oryginał (ang.) |
| Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release |
Collegium Pharmaceutical (COLL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-10-31 13:06:09 |
Czytaj oryginał (ang.) |
| Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2024-10-28 12:46:21 |
Czytaj oryginał (ang.) |
| Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2024-10-11 14:46:59 |
Czytaj oryginał (ang.) |
| Breakouts Boost These Three Stocks To All-Time Highs |
Three stocks, Blue Owl Capital, Collegium Pharmaceuticals and Armstrong World Industries are at their all time high as they break out from proper bases. |
investors.com |
2024-10-04 18:37:34 |
Czytaj oryginał (ang.) |
| Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2024-09-25 14:46:14 |
Czytaj oryginał (ang.) |
| Collegium Pharmaceutical (COLL) Upgraded to Buy: Here's Why |
Collegium Pharmaceutical (COLL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2024-09-09 17:00:21 |
Czytaj oryginał (ang.) |
| Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2024-09-09 14:46:36 |
Czytaj oryginał (ang.) |
| Collegium to Participate in H.C. Wainwright 26th Annual Global Investment Conference |
STOUGHTON, Mass., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference being held in New York, NY from September 9-11, 2024. |
globenewswire.com |
2024-08-30 12:00:00 |
Czytaj oryginał (ang.) |
| Collegium Pharmaceutical, Inc. (COLL) Q2 2024 Earnings Call Transcript |
Collegium Pharmaceutical, Inc. (NASDAQ:COLL ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Christopher James - Vice President of Investor Relations Mike Heffernan - Interim President and Chief Executive Officer, Founder & Chairman Colleen Tupper - Chief Financial Officer Scott Dreyer - Chief Commercial Officer Conference Call Participants David Amsellem - Piper Sandler Les Sulewski - Truist Securities Operator Greetings, and welcome to the Collegium Pharmaceutical Second Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2024-08-09 01:30:09 |
Czytaj oryginał (ang.) |
| Collegium Pharmaceutical (COLL) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates |
Although the revenue and EPS for Collegium Pharmaceutical (COLL) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
zacks.com |
2024-08-08 23:01:18 |
Czytaj oryginał (ang.) |
| Collegium Pharmaceutical (COLL) Beats Q2 Earnings and Revenue Estimates |
Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.62 per share, beating the Zacks Consensus Estimate of $1.56 per share. This compares to earnings of $1.26 per share a year ago. |
zacks.com |
2024-08-08 22:25:31 |
Czytaj oryginał (ang.) |
| Collegium Reports Second Quarter 2024 Financial Results |
– Generated Q2'24 Net Revenue of $145.3 Million and Record Belbuca ® Revenue of $52.2 Million, Up 7% and 21% Year-over-Year, Respectively – |
globenewswire.com |
2024-08-08 20:01:00 |
Czytaj oryginał (ang.) |